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Case ReportsThis case highlights the importance of recognition of
atypical manifestations of SVA, which may lead to missing
a definite diagnosis at first assessment. In our case, the
patient’s primary diagnosis was acute inferior wall MI.
This presentation, combined with electrocardopgraphic
and coronary angiographic results, can easily mislead the
physician to make a definite diagnosis of coronary artery
disease and thus ignore further differential diagnosis,
without probing into the potential cause of the acute MI.
In this case, however, there were some clues. The patient
was young, without any cardiometabolic risk factors or
any atherosclerotic plaques on echocardiography and
angiography, and the exact pathophysiologic mechanism
of acute MI thus needed to be determined. Echocardiogra-
phy plays a key role in the diagnosis of right SVA,
determining the location and size of the rupture
and demonstrating associated lesions.1 Although highly
diagnostic, however, echocardiography is limited in both
sensitivity and accuracy, especially in an emergency
situation. In this case, because the primary impression
was coronary artery disease, SVA went unnoticed at first
glance, thus demonstrating the importance of including
SVA in the differential diagnosis before performing
echocardiography on a young individual without any
cardiometabolic risks who has a sudden acute MI.
The proposed pathophysiologic mechanism in this case
would be that the thrombus developed in the aneurysm of
the right coronary sinus of Valsalva and traveled into the
RCA once the aneurysm ruptured, in turn precipitating
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coronary artery disease changes during the angiographic
procedure and the obstruction was very abrupt, thus rein-
forcing the theory of a thrombus traveling down the RCA.
In addition, during an open cardiac procedure, it was
observed that neither the SVA nor the right SVA affected
the RCA, thus clarifying that the thrombosis of the RCA
was related neither to aneurysmal compression of the
RCA nor to the right SVA encroaching on the ostium of
the RCA. It was also reported that there was thrombosis
in the SVA that moved further and might become a source
of cerebrovascular embolism, causing a thromboembolic
cerebrovascular accident might occur. Shahrabani and col-
leagues2 described a young patient with a large unruptured
aneurysm of the right sinus of Valsalva containing thrombus
who had a history of cardiovascular accident caused by an
embolus to the right middle cerebral artery. Similarly,
Honda and coworkers3 and Luckraz and colleagues4 also
reported SVA protruding into the pulmonary artery.
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1823-5.Early structural valve deterioration of the Trifecta aortic valve
biological prosthesis: A word of cautionPankaj Saxena, FRACS, PhD, Kevin L. Greason, MD, and Hartzell V. Schaff, MD, Rochester, MinnThe St Jude Medical Inc (St Paul, Minn) Trifecta valve is a
relatively new biological prosthesis that completed a multi-
center US Food and Drug Administration Investigational
Device Exemption study in 2011. During a median patientfollow-up of 0.9 years of the 1014 valve implantations in
that study, 1 patient underwent explant of the valve for
structural valve deterioration.1We report an additional case.CLINICAL SUMMARY
A 67-year-old woman presented to us with New York
Heart Association class IV dyspnea and severe Trifecta
prosthetic aortic valve stenosis. She had multiple previous
cardiac operations that included an aortic valve replacement
plus coronary artery bypass graft surgery 18 years
previously, redo coronary artery bypass graft surgery
13 years previously, and repeat aortic valve replacement
with a 21-mm Trifecta valve 4 years previously.ery c January 2014
FIGURE 1. A, Intraoperative transesophageal echocardiography in short-axis view demonstrates thickening and calcification of the prosthetic aortic valve
cusps. B, Color Doppler demonstrates turbulence across the prosthetic aortic valve due to severe aortic stenosis. C, Explanted valve prosthesis from aortic
aspect. D, Explanted valve prosthesis from the ventricular aspect.
Case ReportsShe had dysfunction of the Trifecta valve prosthesis with
echocardiography that demonstrated severe prosthetic valve
stenosis (systolic mean Doppler gradient of 75 mm Hg at a
heart rate of 55 beats/min and an aortic valve area index of
0.35 cm2/m2) and mild valve regurgitation (Figure 1, A and
B). The left ventricular systolic ejection fraction was
normal. Coronary angiogram demonstrated a patent right
internal thoracic artery to left anterior descending coronary
artery bypass graft.
The patient’s Trifecta valve insertion was performed at
another institution, and we do not know the results of her
perioperative echocardiogram. Postoperative surveillance
transthoracic echocardiograms revealed mean gradients
across the prosthetic valve of 6, 7, 29, and 46 mm Hg at
1, 2, 3, and 3.5 years, respectively, after the implantation
of the Trifecta valve. The patient was placed on aspirin
325mg per day at the time of her discharge after the Trifecta
valve replacement. The aspirin was continued up to our
explant of the Trifecta valve.
The patient underwent repeat sternotomy, bicaval and
aortic cannulation, myocardial protection with antegrade
and retrograde cardioplegia, and repeat aortic valve replace-
ment. Operative findings confirmed structural valve degene-
ration of the aortic prosthesis (Figure 1, C and D). We
performed supra-annular implantation of a 21-mm Carbo-
medics Top Hat valve (Sorin Group, Milan, Italy). The
patient had an uncomplicated postoperative course and was
discharged 5 days after the operation. Postoperative echocar-
diography demonstrated normal function of the aortic me-
chanical valve prosthesis and no paravalvular regurgitation.
DISCUSSION
The use of stented aortic biological prosthetic valves has
increased significantly over the last several years because of
improvements in valve design and hemodynamics, and
satisfactory long-term durability without any need for
anticoagulation in the majority of patients. The Trifecta
valve is a bovine pericardial valve with promising short-
term results and satisfactory hemodynamics, especiallyThe Journal of Thoracic and Cafor the small-sized prostheses.1 Long-term studies confirm
the durability of other pericardial valves in the aortic
position with a low probability of explantation.2
Structural valve deterioration of a biological prosthesis is
an important issue after aortic valve replacement. This
phenomenon is not well understood and seems to be
multifactorial. Despite the use of anticalcification agents
such as glutaraldehyde and ethanol, early degeneration of
the valve is still possible from an accelerated immunologic
reaction to the pericardial tissue causing valve failure.3
Early degeneration of bioprosthetic valves has been
reported with other similarly designed pericardial valves
implanted in the aortic position. For example, Alvarez
and colleageus4 reported that 4% patients in a cohort of
491 patients who had aortic valve replacement with the
Mitroflow valve (Model A12; Sorin Group Inc, Mitroflow
Division, Vancouver, Canada) underwent reoperation
after structural valve deterioration at a median follow-up
of 76 months in patients aged more than 70 years.4
CONCLUSIONS
Regular clinical and echocardiographic follow-up of all
patients with bioprosthetic aortic valve replacements
seems reasonable. We recommend this to detect early and
unexpected valve failure.5
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